

SCIENTIFIC REPORTS

OPEN **Corrigendum: Long term outcome of Aldosteronism after target treatments**

Vin-Cent Wu, Shuo-Meng Wang, Chia-Hui Chang, Ya-Hui Hu, Lian-Yu Lin, Yen-Hung Lin, Shih-Chieh Jeff Chueh, Likwang Chen & Kwan-Dun Wu

Scientific Reports 6:32103; doi: 10.1038/srep32103; published online 02 September 2016; updated on 24 March 2017

The original version of this Article contained an error in the Abstract.

“While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.

now reads:

“While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.

This error has now been corrected in the PDF and HTML versions of the Article.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017